Scientists have revealed that they have identified a small protein with a big role in lowering plasma glucose and increasing insulin sensitivity, which can help in controlling diabetes.
Indiana University School of Medicine researchers found that Sestrin 3 plays a critical role in regulating molecular pathways that control the production of glucose and insulin sensitivity in the liver, making it a logical target for drug development for type 2 diabetes and metabolic syndrome, which can produce increased blood pressure, abnormal cholesterol levels and insulin resistance.
Sestrin 3 is a member of a small family of proteins that have long been known to suppress oxidative stress and regulate normal cellular activity, thus making it an important regulator of metabolic homeostasis.
Lead author X. Charlie Dong and his colleagues monitored blood glucose levels and liver insulin sensitivity in mice with the endogenous Sestrin 3 protein and mice genetically engineered to not produce the protein and to examine the regulatory effects of Sestrin 3, the animals were fed a diet with 18 percent of its calories from fat or a high-fat diet with 60 percent of calories from fat.
It was found that the mice without the Sestrin 3 protein had elevated fasting blood glucose levels, indicative of impaired liver insulin sensitivity or poorly regulated glucose metabolism. Both insulin and glucose tolerance tests were significantly better in the mice with the Sestrin 3 protein, leading researchers to believe that the protein plays a critical role in hepatic insulin sensitivity and glucose metabolism.
The researchers said that the findings have significant implications in the prevention and treatment of type 2 diabetes and could prove to be useful targets for modulation of insulin sensitivity and glucose homeostasis and as a target for therapeutic agents to increase liver function to prevent diabetes.
The study was published online in Diabetes, the journal of the American Diabetes Association.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
